Stomach Cancer Trial, Recruiting NCT06915389 Sponsor: Qinghai Red Cross Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06915389
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose overall health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system called ECOG PS 0–2 (confirm with trial site)
  • People who have been diagnosed with gastric (stomach) cancer through a tissue or fluid sample examined in a laboratory
  • People who have not previously been treated with a type of cancer immunotherapy medicine known as a PD-1 or PD-L1 inhibitor
  • People whose life expectancy is at least 3 months
  • People who are willing and able to follow the trial schedule, attend follow-up visits, and sign a consent form agreeing to take part

Who may not be able to join:

  • People whose stomach cancer cannot be confirmed through a tissue sample, either because a sample could not be collected or because there was not enough material to make a diagnosis
  • People who do not wish to receive PD-1 or PD-L1 inhibitor treatment
  • People for whom a blood (plasma) sample taken before immunotherapy treatment begins is not available
  • People who have an autoimmune disease (a condition where the body's immune system attacks its own tissues)
  • People who had serious pre-existing problems with their heart, lungs, thyroid, or other organs before starting immunotherapy
  • People who had significantly abnormal liver function, kidney function, pancreatic enzyme levels, or other related test results before starting immunotherapy
  • People who have any other condition that the research team considers may put them at risk or prevent them from fully participating in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Qinghai Red Cross Hospital
Registry
ClinicalTrials.gov
Start date
22 February 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of immune-related adverse events; Changes in Plasma Metabolite Levels; Changes in Plasma Lipid Levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov